Latest Dilution News

Kingsgate Consolidated has secured a US$25 million standby loan facility with Nebari, significantly reducing its debt and improving financing terms. This move marks a major step in the company’s de-gearing strategy while maintaining funding flexibility.

TerraCom Limited has announced a partially underwritten renounceable entitlement offer aiming to raise approximately A$60 million to bolster its financial position amid ongoing coal price pressures. Key directors have committed to participate, while substantial shareholder Orbit Marketing stands ready to underwrite a significant portion of any shortfall.

ActivEX Limited has completed a $100,000 share placement with Business Victor Investments Limited, aiming to accelerate its exploration activities and strengthen working capital.

Corella Resources has completed the first tranche of a $1 million share placement, issuing over 142 million shares at $0.0035 each. The second tranche and attached options await shareholder approval in early 2026.

Pure Resources has completed a $1.7 million placement to fund its Garnet Hills Garnet and Graphite Project, with options to be issued pending shareholder approval.

Wingara AG Limited has arranged a $250,000 unsecured loan facility from NAOS Asset Management entities, featuring a convertible note option that could reshape its capital structure.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Rox Resources has completed a $200 million capital raise, including a $134 million second tranche placement, to fund development of its Youanmi Gold Project in Western Australia.

Minbos Resources has obtained a crucial ASX waiver allowing it to issue shares under its Share Purchase Plan without the usual shareholder approval, aligning pricing with its recent Placement and aiming to maintain fairness among investors.

Hartshead Resources NL has entered a binding agreement for acquisition by ACAM GP Limited, offering shareholders a 133% premium and a clear exit from development risks. The scheme is set for implementation in early 2026, pending approvals.